MartinAlanMenterMD

PubMed

• 7 citations
  Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
  A P Fernandez, E Dauden, S Gerdes, M G Lebwohl, M A Menter, C L Leonardi, M Gooderham, K Gebauer, Y Tada, J P Lacour, L Bianchi, A Egeberg, I Pau-Charles, A M Mendelso...> ;Journal of the European Academy of Dermatology and Venereology. 2022 Oct 1
• 26 citations
  Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
  Diamant Thaçi, Bruce Strober, Kenneth B Gordon, Peter Foley, Melinda Gooderham, Akimichi Morita, Kim A Papp, Lluís Puig, M Alan Menter, Matthew J Colombo, Yedid Elbez,...> ;Dermatology and Therapy. 2022 Feb 1
• 24 citations
  The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing sur...
  Mark Lebwohl, A. Deodhar, Cem Griffiths, M A Menter, Denis Poddubnyy, Weibin Bao, V Jehl, Kwaku Marfo, P Primatesta, Abhijit Shete, V Trivedi, P. J. Mease> ;The British Journal of Dermatology. 2021 Apr 8
• 13 citations
  Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 rando...
  Mark Lebwohl, Craig L. Leonardi, Nehal N. Mehta, Alice B. Gottlieb, Alan M. Mendelsohn, Jeff Parno, Stephen J. Rozzo, M. Alan Menter> ;Journal of the American Academy of Dermatology. 2021 Feb 1
• 4 citations
  How can we manage the safety concerns associated with the increase in biologics for psoriasis
  Annika Silfvast-Kaiser, Martin Alan Menter> ;Expert Opinion on Drug Safety. 2020 Jan 31
• 9 citations
  Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib.
  Isabel M Haugh, Ian T Watson, M. Alan Menter> ;Proceedings. 2018 Sep 21
• IL-17 inhibitors for psoriasis.
  Paek, S. Y.,Frieder, J.,Kivelevitch, D.,Menter, M. A.> ;Semin Cutan Med Surg. 2018 Sep 15
• Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas.
  Kivelevitch, D.,Frieder, J.,Watson, I.,Paek, S. Y.,Menter, M. A.> ;Expert Opin Pharmacother. 2018 Mar 23
• 11 citations
  Spectrum of orocutaneous disease associations: Immune-mediated conditions
  Jeffrey D. Cizenski, Pablo Michel, Ian T. Watson, Jillian Frieder, Elizabeth G. Wilder, John M. Wright, M. Alan Menter> ;Journal of the American Academy of Dermatology. 2017 Nov 1
• 12 citations
  Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditions
  Elizabeth G. Wilder, Jillian Frieder, Suraj Sulhan, Pablo Michel, Jeffrey D. Cizenski, John Wright, M. Alan Menter> ;Journal of the American Academy of Dermatology. 2017 Nov 1
• A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
  Papp, K. A.,Menter, M. A.,Raman, M.,Disch, D.,Schlichting, D. E.,Gaich, C.,Macias, W.,Zhang, X.,Janes, J. M.> ;Br. J. Dermatol.. 2016 Jan 23
• Awareness and engagement in political advocacy among dermatology residents: A needs assessment.
  Horner, M. E.,Kourosh, A. S.,Menter, M. A.> ;J. Am. Acad. Dermatol.. 2015 Mar 17
• Reply to: "Review of drug-related causes of oculocutaneous disease".
  Mayer, J. E.,Menter, M. A.> ;J. Am. Acad. Dermatol.. 2015 Jan 17
• The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease.
  Horner, M. E.,Abramson, A. K.,Warren, R. B.,Swanson, S.,Menter, M. A.> ;J. Am. Acad. Dermatol.. 2014 Apr 20
• 9 citations
  The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease
  Antoinette Day, Amanda Abramson, Mahir Patel, Richard B. Warren, M. Alan Menter> ;Journal of the American Academy of Dermatology. 2014 May 1
• Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
  Menter, M. A.,Caveney, S. W.,Gottschalk, R. W.> ;J Drugs Dermatol. 2012 Nov 09
• Martin Alan Menter, MD: a conversation with the editor
  Martin Alan Menter> ;Proceedings. 2003 Apr 1
• [The physician''s professional responsibilities, especially the responsibility for patient education].
  Fuchs, S., Menter, M.> ;Z Orthop Ihre Grenzgeb. 1998 Jan 31
• Psoriasis and pregnancy: hormone and immune system interaction.
  Boyd, A. S., Morris, L. F., Phillips, C. M., Menter, M. A.> ;Int J Dermatol. 1996 Mar
• Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994.
  Menter, M. A., See, J. A., Amend, W. J., Ellis, C. N., Krueger, G. G., Lebwohl, M., Morison, W. L., Prystowsky, J. H., Roenigk, H. H., Shupack, J. L., Silverman, A. K....> ;J Am Acad Dermatol. 1996 Feb
• 47 citations
  Methotrexate and reproduction in men: Case report and recommendations
  Laura F. Morris, Mary Jo Harrod, M. Alan Menter, Alan Silverman> ;Journal of the American Academy of Dermatology. 1993 Nov 1
• 13 citations
  Resistant childhood psoriasis: an analysis of patients seen in a day-care center.
  M. Alan Menter, David A. Whiting, R N Joyce McWilliams> ;Pediatric Dermatology. 1984 Jul 1
• Hypertrichosis lanuginosa and a lichenoid eruption due to diazoxide therapy.
  Menter, M. A.> ;Proc R Soc Med. 1973 Apr 01
• Pemphigus vulgaris in a boy aged thirteen.
  Menter, M. A., Bell, A. A., Wells, R. S.> ;Guys Hosp Rep. 1973 Jan 01
• Actinic reticuloid: an immunological investigation providing evidence of basement membrane damage.
  Menter, M. A., McKerron, R. A., Amos, H. E.> ;Br J Dermatol. 1974 May 01
• Join now to see all